ReadeRx Therapeutics
RNA-based Cancer Therapeutics
StartupReadeRx Therapeutics is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2023. RNA-based Cancer Therapeutics. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- Last RoundUndisclosed
What does ReadeRx Therapeutics do?
ReadeRx is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer. IGF2BP1 is an oncofetal RNA binding protein expressed in many types of cancers. it regulates RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. IGFB2P1 is widely expressed in development but is dramatically reduced in normal mature tissues. In many cancers IFG2BP1 is reactivated, assuming a pivotal role in stabilizing key pro-oncogenic RNAs, thereby promoting pro-oncogenic and pro-tumorigenic processes. Consequently, the inhibition of IGF2BP1 emerges as a highly promising strategy for cancer therapy.
What sector is ReadeRx Therapeutics in?
ReadeRx Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is ReadeRx Therapeutics located?
ReadeRx Therapeutics is based in Tel Aviv-Yafo, Israel.